AI and Cancer Research ── 2026-11-12
New papers on cancer and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 13 themes, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
All cancers: Cancer biology(2)
Hematologic malignancies: AML(0) · CML(0) · ALL(0) · CLL(0) · Lymphoma(0) · Myeloma(0)
Solid tumors: Breast(1) · Lung(2) · Colorectal(0) · Pancreatic(2) · Prostate(2) · Brain(2) · Ovarian(0) · Endometrial(1) · Gastric(0) · Liver(0) · Kidney(0) · Bladder(0)
Rare cancers: ACC(0)
Cancer molecular biology and AI
- Abstract
Whole-slide image (WSI) survival prediction is complicated by heterogeneous tumor morphology, where prognostic evidence is distributed across tumor, stroma, immune infiltration, necrosis, and residual tissue regions and often appears as mixed patch-level tissue evidence. Existing models commonly aggregate patch embeddings directly or convert tissue cues into hard pseudo-labels, which can discard uncertainty at tumor-microenvironment interfaces. We propose a prior-guided WSI survival framework that uses soft histopathologic priors derived from the CONCH vision-language foundation model. Prompt-similarity scores are normalized into patch-level tissue distributions and used to guide probability-weighted tissue-prototype initialization, entropy-weighted prior-consistency learning, and prototype-conditioned graph-context aggregation over a spatial k-nearest-neighbor graph. The residual Others class is retained for representation learning but excluded from prognostic prior alignment. In patient-level 5-fold cross-validation on TCGA KIRC, KIRP, LUAD, STAD, and UCEC cohorts, the model achieved C-index values of 0.7307, 0.8153, 0.6375, 0.6744, and 0.7029, respectively, matching or exceeding the strongest baseline in every cohort. Kaplan-Meier analysis showed significant high-versus low-risk separation across all cohorts, and ablation studies confirmed the contributions of soft priors, entropy weighting, the Others channel, and graph-context aggregation. These results show that retaining patch-level histopathologic uncertainty provides a consistent and interpretable signal for WSI-based survival risk stratification.
Journal IF-equivalent: 2.0 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-11; not the official Clarivate IF)Reference: Wang S, Chen Y, Zhang L, Li X, Huang Y, Li X, et al. Prior-guided whole-slide survival prediction with soft histopathologic priors from vision-language foundation models. Biomed Phys Eng Express. 2026 Nov 9 [Epub ahead of print]. doi:10.1088/2057-1976/aebfa5.Checked: Abstract only - Abstract
Cancer biomarkers should be specific, reproducible, and accessible from practical biological samples. Although omics-based approaches have substantially advanced biomarker discovery, many strategies still rely on individual molecules or limited molecular panels, which may not fully capture the complexity of tumor biology. Whether tumor-associated chemical signatures can improve cancer detection remains an open question. Here, we investigated whether a breast tumor-associated multi-ion signature could be detected in mammary gland tissue from the MMTV-PyMT breast cancer mouse model, as well as in liver, serum, and fur collected from the same animals. Low-mass ions ( m / z 50-250) were analyzed using time-of-flight secondary ion mass spectrometry (ToF-SIMS) combined with multivariate analysis and machine learning. A robust mammary tumor multi-ion signature reliably distinguished tumor-bearing from healthy mice, with both partial least squares-discriminant analysis (PLS-DA) and random forest achieving an area under the receiver operating characteristic curve (AUC) of 0.997 under leave-one-animal-out cross-validation. Animal-label permutation testing confirmed that classification performance was significantly greater than expected by chance, and 98 of 313 ions differed significantly at the animal level. While liver and serum samples showed little evidence of tumor-associated discrimination, fur showed the highest classification performance and the greatest overlap in discriminative ions with mammary tissue. These findings demonstrate that low-mass ToF-SIMS enables robust identification of mammary tumor-associated multi-ion signatures, but that their detectability varies across biological matrices. Although the evidence in fur remained exploratory, it suggests that some tumor-associated chemical information may extend beyond the primary tumor and warrants further investigation of hair and related minimally invasive samples for cancer detection.
Journal IF-equivalent: 3.7 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-11; not the official Clarivate IF)Reference: Manaprasertsak A, Tang W, Lööf C, Azemovic L, Mohlin S, Hagerling C, et al. Integrating ToF-SIMS and machine learning reveals a mammary tumor-associated multi-ion signature. Analyst. 2026 [Epub ahead of print]. doi:10.1039/d6an01090c.Checked: Abstract only
See all 2 Cancer biology papers →
Hematologic malignancies
Acute myeloid leukemia (AML): treatment, trials and AI
No new qualifying paper for this issue.
Chronic myeloid leukemia (CML): treatment, trials and AI
No new qualifying paper for this issue.
Acute lymphoblastic leukemia (ALL): treatment, trials and AI
No new qualifying paper for this issue.
Chronic lymphocytic leukemia (CLL): treatment, trials and AI
No new qualifying paper for this issue.
Lymphoma: treatment, trials and AI
No new qualifying paper for this issue.
Multiple myeloma: treatment, trials and AI
No new qualifying paper for this issue.
Solid tumors
Breast cancer: treatment, trials and AI
- Abstract
Background: Breast cancer is one of the most common malignancies among women worldwide and remains one of the leading causes of cancer-related mortality. Accurate prediction of breast cancer recurrence is clinically important for patient survival, treatment planning, and follow-up strategies. However, recurrence prediction remains challenging due to high-dimensional feature spaces, class imbalance, limited sample size, and noisy variables in medical datasets.
Methods: In this study, an integrated machine learning framework combining hybrid ensemble learning, data balancing, and optimization-based feature selection is proposed for breast cancer recurrence prediction. In the proposed approach, different classifiers were comparatively evaluated, and the XGBoost + SVM hybrid model was selected based on its performance in terms of recall and F1-score. To address class imbalance, ADASYN was employed to increase the representation of recurrence cases during training. Feature selection was subsequently performed by combining Optuna and Ant Colony Optimization (ACO) to identify a smaller subset of informative features.
Results: The framework was developed and evaluated primarily on the Breast Cancer Wisconsin Prognostic (WPBC) dataset, where it achieved an accuracy of 93.30%, an F1-score of 86.60%, a recall of 91.30%, and an AUC of 95.86%. To examine its applicability to other breast cancer classification tasks, the same modeling approach was also evaluated on the Breast Cancer Wisconsin Diagnostic (WDBC) and Wisconsin Breast Cancer Original (WBC) datasets. The corresponding AUC values were 99.91% and 98.74%, respectively.
Conclusions: These findings suggest that the integration of XGBoost + SVM, ADASYN-based class balancing, and Optuna + ACO-based feature selection can contribute to breast cancer recurrence prediction on the WPBC dataset. The additional experiments on WDBC and WBC further indicate that the proposed modeling approach is applicable to breast cancer classification tasks with different feature structures and prediction targets.
Journal IF-equivalent: 5.4 (OpenAlex 2-year mean citedness, value as of 2026-10-23, retrieved 2026-10-24; not the official Clarivate IF)Reference: Altuntaş D, Aymaz Ş. A Comprehensive Framework for Breast Cancer Recurrence Prediction Using Class Balancing and Feature Optimization Techniques. Biomedicines. 2026 Nov 9;14(11):2579. doi:10.3390/biomedicines14112579.Checked: Abstract only
Lung cancer: treatment, trials and AI
- Abstract
BACKGROUND: Although adaptive radiotherapy (ART) has many advantages, its high resource demands limit routine clinical application. Developing prediction models for tumor regression based on radiomics and dosiomics may help identify NSCLC patients who can benefit METHODS: This retrospective study included 116 NSCLC patients. Tumor regression was assessed by the change in gross tumor volume (GTV) after 18-20 fractions. Radiomics and dosiomics features were extracted and fused. Feature selection was performed using random forest, principal component analysis, and XGBoost. SVM models were then constructed based on radiomics, dosiomics, and fused features. Features from the optimal single-omics models were further integrated to develop a combined model. Performance was evaluated via ROC analysis, calibration, and decision curve analysis. For tumor regression sensitive patients, CBCT images were processed to generate synthetic CT (sCT). The 10th-fraction sCT was subsequently used to examine lung dose changes and their association with tumor volume reduction. RESULTS: No significant differences were observed in clinical characteristics between the two groups of tumor regression. On the validation set, the combined model achieved the best predictive performance with an AUC of 0.811, outperforming the radiomics, dosiomics, and fused models (AUCs: 0.750, 0.778, 0.756, respectively). The fused model did not show advantages over the single-omics model. At the 10 fraction, lung dose parameters had increased and exhibited a linear correlation with tumor volume reduction, suggesting that early dose variation may serve as potential indicators for ART. CONCLUSIONS: This study aims to integrate radiomics and dosiomics to construct a predictive model for tumor regression during radiotherapy for NSCLC, with the combined model achieving the best predictive performance. Preliminary dose verification based on CBCT demonstrated the feasibility of early ART for tumor regression sensitive patients.
Journal IF-equivalent: 2.2 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Zhang F, Zhang L, Li Z, Hu X, Liu Z. Integrating radiomics and dosiomics to predict tumor regression for early adaptive radiotherapy in NSCLC patients. Applied Radiation and Isotopes. 2027 Jan;239:113096. doi:10.1016/j.apradiso.2026.113096.Checked: Abstract only - Abstract
BACKGROUND: Computed tomography (CT)-based noninvasive prediction of epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) is highly important for advancing precision diagnosis and treatment. Current detection methods that rely on invasive tissue biopsies present several limitations. This study aimed to develop a model that integrated deep learning and multimodal information for the noninvasive prediction of EGFR-sensitizing mutations (exon 19 deletion and L858R point mutation) in NSCLC patients using contrast-enhanced CT (CE-CT) images. METHODS: We retrospectively included 466 pathologically confirmed NSCLC patients from two centers (413 from our own center for model development and internal validation, and 53 from another center for independent external validation), and proposed a novel paradigm combining disentangled self-supervised learning (D-SSL) with multimodal gated fusion. The D-SSL encoder was pretrained on CT images and tumor ROI masks from the entire 413-patient internal cohort without using EGFR mutation labels and was subsequently fixed for downstream classification. An adaptive gated fusion network was subsequently constructed to dynamically integrate these deep features with traditional radiomics features and clinical information to predict the EGFR-sensitizing mutation status. RESULTS: In 20 repeated random splits, the D-SSL fusion models achieved mean AUCs of 0.800 (±0.052) and 0.794 (±0.048) on the training set and internal test set, respectively. One-way ANOVA and subsequent Tukey HSD post-hoc test revealed that the performance on the internal test set of the D-SSL fusion models was significantly superior to that of the clinical models, radiomics models, and radiomics-clinical fusion models (all p < 0.001). On the fully independent external validation set, which was not involved in D-SSL pretraining or downstream model development, the D-SSL fusion models maintained robust performance with a mean AUC of 0.680 (±0.038). Ablation studies showed that models using only the shape head or only the texture head achieved mean AUCs of 0.680 (±0.023) and 0.684 (±0.028), respectively, both significantly lower than that of the complete D-SSL fusion models (both p < 0.001), confirming the complementarity of shape and texture features. Subgroup analysis demonstrated that the model achieved accuracies significantly above the random chance level (50%) in female 83.65% (±3.97%), male 68.90% (±3.72%), smoker 85.07% (±4.41%), and nonsmoker 69.21% (±3.44%) subgroups, suggesting that it did not merely rely on clinical features but captured deep imaging phenotypes associated with EGFR-sensitizing mutations. Feature visualization analysis demonstrated that the D-SSL feature space could effectively distinguish among various imaging manifestation types and pathological categories, confirming the model's ability to capture highly discriminative and clinically meaningful imaging phenotypes. CONCLUSIONS: This study developed a framework integrating D-SSL and multimodal fusion for the noninvasive prediction of EGFR-sensitizing mutations in NSCLC. The framework demonstrated strong discrimination in the internal transductive evaluation and retained predictive value in a fully independent external cohort. These findings support the potential of self-supervised representation learning and gated multimodal fusion, while larger multicenter studies using strictly inductive split-before-pretraining designs remain necessary.
Journal IF-equivalent: 8.6 (OpenAlex 2-year mean citedness, value as of 2026-11-03, retrieved 2026-11-05; not the official Clarivate IF)Reference: Jin J, Cai H, Liu Y, Cai W, Han H, Hu M, et al. EGFR mutation prediction in NSCLC from CT images via self-supervised disentangled feature learning and multimodal fusion. J Transl Med. 2026 Aug 11;24(1):1406. doi:10.1186/s12967-026-08778-8.Checked: Abstract only
Colorectal cancer: screening, treatment, trials and AI
No new qualifying paper for this issue.
Pancreatic cancer: treatment, trials and AI
- Abstract
BACKGROUND: Accurate interpretation of pancreatic cancer status and resectability-related information, together with effective perioperative communication, remains a major challenge in pancreatic cancer care. In routine practice, unstructured computed tomography (CT) reports and complex clinical information may limit the accessibility and consistency of clinical information delivery and increase the communication burden on clinicians. Large language models (LLMs) offer new opportunities for clinical information support; however, existing applications are often task-specific and rarely combine CT report interpretation with perioperative consultation within a unified patient-oriented framework. OBJECTIVE: This study aimed to develop and retrospectively evaluate PancreaGuide, a knowledge-augmented LLM agent designed to support clinician-supervised CT report-based interpretation of pancreatic cancer resectability-related information and standardized perioperative consultation. METHODS: We developed PancreaGuide, an agent-based framework integrating structured prompting, retrieval-augmented generation, and a domain-specific pancreatic surgery knowledge base to support clinical information interpretation and perioperative consultation. A retrospective cohort of 444 patients who underwent contrast-enhanced CT at West China Hospital between 2023 and 2025 was analyzed. Three LLMs, ChatGPT, DeepSeek, and Gemini, were evaluated in both base and PancreaGuide-integrated configurations. CT report-based interpretation of resectability-related information was evaluated using accuracy, sensitivity, specificity, positive predictive value, negative predictive value, F 1 -score, receiver operating characteristic curves (ROCs), and decision curve analysis (DCA) using a surgery-based proxy reference. Perioperative consultation quality was evaluated across 5 dimensions: accuracy, completeness, consistency, safety, and robustness. RESULTS: Higher classification metric point estimates were observed after integration of the PancreaGuide framework across all 3 backbone models. In CT report-based interpretation of resectability-related information, Gemini+ achieved the highest accuracy of 87.4% (95% CI 0.840-0.902) and a sensitivity of 95.9% (95% CI 0.927-0.978). All models showed improved sensitivity and specificity estimates after PancreaGuide integration, with improved agreement between model-generated interpretations and observed surgical management status. ROC and DCA suggested improved discrimination and estimated net benefit using the surgery-based proxy reference. In perioperative consultation, PancreaGuide-integrated models received higher expert-rated scores than their corresponding base models across all 5 evaluation dimensions. Gemini+ achieved the highest overall score (mean 3.88, SD 0.38), followed by ChatGPT+ (mean 3.8, SD 10.36) and DeepSeek+ (mean 3.75, SD 0.35). The greatest improvements were observed in completeness and robustness, with consistent gains across clinical consultation domains. CONCLUSIONS: PancreaGuide provides a unified, knowledge-augmented framework for clinician-supervised CT report-based interpretation of resectability-related information and perioperative information support across multiple LLM backbones. The CT-based findings should be interpreted as agreement with observed surgical management status rather than validation against an independently adjudicated anatomical resectability. PancreaGuide may serve as an auxiliary information interpretation framework to improve the accessibility and consistency of clinical information delivery, while it should not replace formal radiological assessment, multidisciplinary evaluation, or clinician judgment.
Journal IF-equivalent: 11.8 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-11; not the official Clarivate IF)Reference: Kuang T, Wang R, Zhang S, Sun Y, Zhou J, Wu Z, et al. PancreaGuide for Computed Tomography Report Interpretation and Perioperative Consultation in Pancreatic Cancer: Development and Retrospective Evaluation of a Knowledge-Augmented Large Language Model Agent. J Med Internet Res. 2026 Nov 9;28:e101607-e101607. doi:10.2196/101607.Checked: Abstract only - Abstract
Accurate early prediction and multi-stage diagnostic classification compliant with AJCC TNM staging criteria are essential for effective treatment planning in pancreatic cancer. Although deep learning (DL) approaches show promising results, interpreting their predictions remains challenging. This study proposes Squeeze-and-Excitation Visual-Efficient Tabular Network (SE-VETNet), an interpretable multimodal DL framework designed for early prediction and multi-stage pancreatic cancer diagnostic classification using medical imaging and clinical data. The framework integrates Visual Geometry Group (VGG) and EfficientNet architectures enhanced with Squeeze-and-Excitation (SE) blocks for feature recalibration, alongside Tabular Network (TabNet) for clinical feature extraction. Attention mechanisms identify relevant tumor characteristics and clinical attributes. An optimized processing pipeline preserves image details and clinical data integrity while improving computational efficiency. To address class imbalance, balancing is applied exclusively to training data, while five-fold cross-validation supports robust evaluation and minimizes potential bias. Experiments demonstrate consistent performance across all folds, achieving a mean test accuracy of 99.21% with minimal variability across five diagnostic cohorts (Healthy and T1–T4). Furthermore, Explainable Artificial Intelligence (XAI) techniques, including Gradient-weighted Class Activation Mapping (Grad-CAM), quantitatively validated against expert ground-truth masks via Intersection over Union (IoU), and TabNet attention, provide insights into image-based and clinical feature contributions, respectively. By integrating multimodal learning, robust evaluation, and explainability, SE-VETNet offers a promising approach to early pancreatic cancer prediction, multi-stage staging, and transparent clinical decision-making. However, validation using independent and diverse clinical datasets remains necessary to establish generalizability and assess its suitability for practical deployment.
Journal IF-equivalent: 3.5 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-11; not the official Clarivate IF)Reference: AbdelAziz NM, Fawzy AM, Shehata EK, AbdelHafeez MM. An Explainable Multimodal Deep Learning Framework for Early Pancreatic Cancer Prediction from Imaging and Clinical Data. Sci. 2026 Nov 9;8(11):360. doi:10.3390/sci8110360.Checked: Abstract only
Prostate cancer: treatment, trials and AI
- Abstract
Introduction: Whether bone metastasis is present at diagnosis determines curative versus systemic treatment of prostate cancer, yet referral for advanced staging relies on imperfect risk stratification; magnetic resonance imaging (MRI) radiomics has been proposed to predict metastatic status from routinely acquired staging imaging.
Methods: This systematic review (PROSPERO CRD420261463568) searched PubMed, Embase and Cochrane CENTRAL for studies of radiomic, deep-learning or hybrid models predicting bone-metastatic status from prostate MRI; incremental value over clinical predictors, reporting completeness, radiomics methodology and risk of bias were appraised.
Results: Six retrospective studies (1240 patients, 491 with bone metastasis, all from China; 322 contributed to the principal validation estimates) were included. Clinical-plus-radiomics models achieved validation areas under the receiver operating characteristic curve (AUCs) of 0.893–0.920 internally and 0.903 externally, with the highest estimate (0.928) from a multimodal model lacking clinical predictors. Only two studies compared clinical-only with combined models (AUC increments of 0.060 and 0.081).
Conclusions: Reported discrimination was generally high, but current evidence cannot establish that radiomics adds value beyond routine clinical predictors. These models are best understood as predictive biomarkers rather than detection tools; a potential triage role among patients below routine staging thresholds remains untested, and transportability beyond the high-prevalence cohorts studied is unproven; prospective multicentre validation is required before clinical use.
Journal IF-equivalent: 4.9 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-11; not the official Clarivate IF)Reference: Clausen NA, Temperley HC, Mulhall CB, Curtain BMM, McLoughlin LC, Kelly ME, et al. Radiomics-Based Prediction of Bone Metastases from Baseline Prostate MRI in Prostate Cancer: A Systematic Review and Critical Appraisal. BioTech. 2026 Nov 8;15(5):102. doi:10.3390/biotech15050102.Checked: Abstract only - Abstract
Prostate cancer is one of the most common and dangerous malignancies in men globally, and so a systematic and mathematically rigorous approach should be used to assess and rank therapeutic agents. This study introduces the computational model which combines graph theoretic molecular descriptors, fuzzy machine learning and fuzzy multi-criteria decision making in analyzing and ranking prostate cancer drugs. The molecular graphs of the selected prostate cancer drugs are partitioned based on their eccentricity, and a set of topological indices are obtained. These indices are structural finger prints that encode the geometry and connectivity of every drug molecule in a mathematically accurate way. Two fuzzy machine learning models, i.e. Fuzzy Random Forest (Fuzzy RF) and Fuzzy Artificial Neural Network (Fuzzy ANN), are used to predict the physicochemical properties of the drug candidates. The models provide accurate and reliable predictions that effectively capture the inherent uncertainty in molecular property data by integrating fuzzy logic into the learning process, as validated through comparison with conventional (non-fuzzy) baseline models. The predicted physicochemical properties and the calculated topological indices are subsequently analyzed by the Fuzzy Measurement of Alternatives and Ranking based on the Compromise Solution (Fuzzy MARCOS), the Fuzzy MARCOS, which is an effective fuzzy multi-criteria approach to decision-making. This strategy involves comparing all drug candidates simultaneously to an ideal and an anti-ideal reference point, which results in an uncertainty aware ranking and an in silico objective prioritization of each drug candidate taking into account both structural and physicochemical features. The findings indicate that the suggested integrated model offers a clear, coherent, and mathematically justified foundation of the evaluation of drugs used in prostate cancer, which can be useful to pharmaceutical scientists and clinical decision makers.
Journal IF-equivalent: 3.1 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Ahmed W, Raza A, Zaman S, Abbas M, Ali P. Multi-criteria drug ranking for prostate cancer using graph-theoretic descriptors and fuzzy machine learning with MARCOS decision analysis. Computational Biology and Chemistry. 2027 Feb;126:109499. doi:10.1016/j.compbiolchem.2026.109499.Checked: Abstract only
Brain tumours: treatment, trials and AI
- Abstract
Public brain metastasis MRI cohorts are widely used for prognostic modeling, but whether an endpoint is identifiable at the available sample size is rarely tested. We evaluated eight clinical endpoints in two public cohorts, Yale/BraTS-MET (199 patients, 74 deaths) and OpenBTAI/MOLAB (75 patients, all deceased), using lesion-centered nnU-Net encoder embeddings and PyRadiomics features with patient-grouped cross-validation and label permutation. Patient-level infratentorial involvement served as a positive control (balanced accuracy 0.60); the Graded Prognostic Assessment (GPA) score was recoverable from OpenBTAI radiomics (ρ = 0.42), whereas brain age was not recovered in either cohort. Primary tumor type was the only endpoint significant after multiplicity correction (1.3× chance). Survival endpoints were null for clinical models and the planned graph model (C = 0.50, p = 0.49); an exploratory linear model on embeddings reached C ≈ 0.58 (p = 0.07, uncorrected), which PyRadiomics features did not reproduce. No progression definition remained significant after family-wise correction. In simulation, 80% power required a true C-index of about 0.68–0.76, so null survival results cannot exclude moderate effects. GPA did not stratify survival (p = 0.18) in a cohort containing only deceased patients. An extraction error found during revision was corrected.
Journal IF-equivalent: 4.3 (OpenAlex 2-year mean citedness, value as of 2026-10-15, retrieved 2026-10-16; not the official Clarivate IF)Reference: Bao X, Wang J, Zhao X. Survival Prediction from Public Brain Metastasis MRI Cohorts: A Positive-Control and Permutation-Based Feasibility Evaluation. J Imaging. 2026 Nov 8;12(11):560. doi:10.3390/jimaging12110560.Checked: Abstract only - Abstract
Postoperative magnetic resonance imaging (MRI) captures anatomical and tissue characteristics relevant to glioma prognosis. We evaluated the contribution of compartment-specific imaging features to clinical and molecular prediction using MU-Glioma-Post. Of 187 patients with usable radiomics, 111 were eligible for 180-day recurrence/progression prediction and 114 were eligible for 365-day mortality prediction after the first available postoperative MRI (TP1). Clinical-only, radiomics-only, and combined elastic-net logistic models were assessed using nested cross-validation and a locked internal holdout. For recurrence, the combined model achieved development out-of-fold (OOF) and holdout areas under the receiver operating characteristic curve (AUROCs) of 0.742 and 0.786 (95% confidence interval, 0.562–0.959), respectively. Morphology was the highest-ranking imaging-only configuration (OOF AUROC, 0.724), and flatness of the surrounding non-enhancing FLAIR hyperintensity led the SHAP feature ranking. In exploratory repeated nested cross-validation, adding shape, volume, and region-presence features to clinical predictors increased mean recurrence AUROC from 0.743 to 0.794, compared with 0.747 for clinical predictors combined with full radiomics. Clinical predictors remained the main source of mortality discrimination, with mean AUROCs of 0.774 for clinical predictors, 0.777 with morphology, and 0.768 with full radiomics. These findings identify postoperative geometry as a promising source of recurrence-related information and support focused integration of morphological features with clinical predictors.
Journal IF-equivalent: 7.1 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-11; not the official Clarivate IF)Reference: Farokhi Nia S, Shafaie V, Movahedi Rad M. Clinical-Radiomic Integration for Postoperative Glioma Recurrence and Survival Prediction. Mach Learn Knowl Extr. 2026 Nov 8;8(11):372. doi:10.3390/make8110372.Checked: Abstract only
Ovarian cancer: treatment, trials and AI
No new qualifying paper for this issue.
Endometrial cancer: treatment, trials and AI
- Abstract
OBJECTIVE: Preoperative identification of non-endometrioid endometrial carcinoma (NEEC) is clinically important because non-endometrioid histology may influence risk assessment and treatment planning. This study aimed to develop and externally validate a transvaginal ultrasound-based deep learning radiomics (DLR) model for preoperative identification of NEEC. METHODS: A total of 663 patients with pathologically confirmed endometrial carcinoma from 11 centers were retrospectively included. The training cohort consisted of 483 patients from eight centers, including 161 NEEC and 322 EEC cases. An independent external test cohort included 180 patients from three additional centers, including 60 NEEC and 120 EEC cases. Radiomics features were extracted using PyRadiomics, and deep learning features were extracted using ResNet-101. Radiomics, deep learning, and combined DLR models were developed using machine learning classifiers and evaluated by receiver operating characteristic analysis, calibration curves, decision curve analysis, and external validation. RESULTS: The combined DLR model achieved the best diagnostic performance among the three models. In the external test cohort, the DLR model yielded an AUC of 0.837, with an accuracy of 0.756, sensitivity of 0.800, and specificity of 0.733. The DLR model outperformed the radiomics model and the deep learning model in both the training and external test cohorts. CONCLUSION: The transvaginal ultrasound-based DLR model showed potential as a noninvasive tool for preoperative identification of NEEC. This model may provide complementary information for individualized preoperative assessment, although prospective validation is required before clinical implementation.
Journal IF-equivalent: 2.3 (OpenAlex 2-year mean citedness, value as of 2026-11-09, retrieved 2026-11-11; not the official Clarivate IF)Reference: Liu X, Xiao W, Jia Y. Transvaginal ultrasound-based deep learning radiomics for preoperative identification of non-endometrioid endometrial carcinoma: A multicenter study. Clinical Imaging. 2027 Jan;141:110979. doi:10.1016/j.clinimag.2026.110979.Checked: Abstract only
See all 1 Endometrial papers →
Gastric cancer: treatment, trials and AI
No new qualifying paper for this issue.
Liver cancer: treatment, trials and AI
No new qualifying paper for this issue.
Kidney cancer: treatment, trials and AI
No new qualifying paper for this issue.
Bladder cancer: treatment, trials and AI
No new qualifying paper for this issue.
Rare cancers
Adenoid cystic carcinoma: treatment, trials and AI
No new qualifying paper for this issue.